All products / DC10150
Tenalisib
Pack sizes and prices
| Pack size | Price |
|---|---|
| 100 mg | $700 USDRequest a quote → |
| 250 mg | $1,400 USDRequest a quote → |
| 1 g | $2,800 USDRequest a quote → |
In stock. Contact our team for lead time, shipping and final quotation.
Product overview
Tenalisib shows selectivity over PI3K α (>300-fold) and β (>100-fold) isoforms. Tenalisib exhibits modest proliferation inhibition (33-46% inhibition @ 10 μM) in both HEL-RS and HEL-RR cells. Addition of 10 μM tenalisib to ruxolitinib is synergistic resulting in a near-complete inhibition of proliferation (>90% for HEL-RS and >70% for HEL-RR). Addition of 5 μM tenalisib, 4 h prior to the addition of ruxolitinib results in a significant reduction in EC50of ruxolitinib (5.8 μM) in HEL-RR cells. Incubation of 10 μM tenalisib with ruxolitinib for 72 h increases the percent of apoptotic cells (55% in HEL-RS and 37% in HEL-RR) compared to either agent alone (16-27% in HEL-RS and 17-21% in HEL-RR).Tenalisib has been well tolerated in subjects with heavily pre-treated relapsed/refractory hematologic malignancies. Reported toxicities are manageable with no DLTs. Single agent activity is evident in difficult-to-treat subjects at ≥ 200 mg BID.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC10150 |
|---|---|
| Product name | Tenalisib |
| CAS | 1639417-53-0 |
| Molecular formula | C23H18FN5O2 |
| Molecular weight | 415.42 |
| Purity | >98% |
| SMILES | O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4NC=NC4=NC=N3)CC)OC5=CC=CC=C15 |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — Tenalisib (DC10150)